S&P 500
(-0.88%) 4 967.23 points
Dow Jones
(0.56%) 37 986 points
Nasdaq
(-2.05%) 15 282 points
Oil
(0.62%) $83.24
Gas
(0.17%) $1.760
Gold
(0.36%) $2 406.70
Silver
(1.29%) $28.75
Platinum
(-1.17%) $943.30
USD/EUR
(-0.14%) $0.938
USD/NOK
(-0.28%) $11.01
USD/GBP
(0.55%) $0.808
USD/RUB
(-0.96%) $93.00

Realtime updates for Aarti Drugs Limited [AARTIDRUGS.NS]

Exchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Upcoming Earnings Alert

2 days till quarter result
(bmo 2024-04-22)

Expected move: +/- 4.43%

Last Updated19 Apr 2024 @ 06:00

0.54% INR 495.00

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 06:00):

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene...

Stats
Today's Volume 104 914
Average Volume 243 378
Market Cap 45.51B
EPS INR0 ( 2024-04-13 )
Next earnings date ( INR0 ) 2024-04-22
Last Dividend INR1.000 ( 2023-02-08 )
Next Dividend INR0 ( N/A )
P/E 25.32
ATR14 INR0.560 (0.11%)

Volume Correlation

Long: -0.19 (neutral)
Short: 0.35 (neutral)
Signal:(39.524) Neutral

Aarti Drugs Limited Correlation

10 Most Positive Correlations
BBL.NS0.955
RBLBANK.NS0.954
AIRAN.NS0.949
PGHH.NS0.944
KELLTONTEC.NS0.94
HPL.NS0.94
PREMEXPLN.NS0.939
SJVN.NS0.938
TWL.NS0.936
POLYCAB.NS0.934
10 Most Negative Correlations
LTGILTBEES.NS-0.947
SINTEX.NS-0.924
RAJRILTD.NS-0.922
BOHRAIND.NS-0.92
RAJVIR.NS-0.911
BGLOBAL.NS-0.906
IRISDOREME.NS-0.906
OMAXE.NS-0.905
JPINFRATEC.NS-0.903
SRPL.NS-0.901

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aarti Drugs Limited Correlation - Currency/Commodity

The country flag 0.76
( moderate )
The country flag 0.77
( moderate )
The country flag 0.15
( neutral )
The country flag 0.68
( moderate )
The country flag -0.83
( strong negative )
The country flag 0.42
( neutral )

Aarti Drugs Limited Financials

Annual 2022
Revenue: INR27.16B
Gross Profit: INR8.28B (30.47 %)
EPS: INR17.96
Q3 2023
Revenue: INR6.06B
Gross Profit: INR2.01B (33.12 %)
EPS: INR3.99
Q2 2023
Revenue: INR6.42B
Gross Profit: INR2.13B (33.12 %)
EPS: INR4.29
Q1 2023
Revenue: INR6.61B
Gross Profit: INR2.15B (32.48 %)
EPS: INR5.17

Financial Reports:

No articles found.

Aarti Drugs Limited Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
INR0
(N/A)
INR0
(N/A)
INR1.000
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)

Aarti Drugs Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.77 - low (58.39%) | Divividend Growth Potential Score: 3.36 - Decrease likely (32.90%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend INR0.150 2003-11-13
Last Dividend INR1.000 2023-02-08
Next Dividend INR0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 32 --
Total Paid Out INR15.88 --
Avg. Dividend % Per Year 0.23% --
Score 2.13 --
Div. Sustainability Score 4.77
Div.Growth Potential Score 3.36
Div. Directional Score 4.06 --
Next Divdend (Est)
(2024-10-31)
INR0 Estimate 0.00 %
Dividend Stability
0.08 Very Bad
Dividend Score
2.13
Pay Frequency
Annually
Yearly Payout
Year Amount Yield
2003 INR0 0.00%
2004 INR0 0.00%
2005 INR0 0.00%
2006 INR0 0.00%
2007 INR0 0.00%
2008 INR0 0.00%
2009 INR0 0.00%
2010 INR0 0.00%
2011 INR0 0.00%
2012 INR0 0.00%
2013 INR0 0.00%
2014 INR0 0.00%
2015 INR0 0.00%
2016 INR0 0.00%
2017 INR0 0.00%
2018 INR0.250 0.18%
2019 INR0.250 0.17%
2020 INR3.00 2.03%
2021 INR0 0.00%
2022 INR1.000 0.18%
2023 INR1.000 0.22%
2024 INR0 0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
TORNTPHARM.NS Dividend Junior 2023-06-23 Annually 22 0.85%
PGHL.NS Dividend Junior 2023-11-13 Annually 22 0.95%
JINDALSTEL.NS Dividend Junior 2023-08-18 Sporadic 25 0.25%
DELTACORP.NS Dividend Junior 2023-07-07 Annually 17 0.39%
SKFINDIA.NS Dividend Junior 2023-06-28 Annually 22 0.93%
MGEL.NS Dividend Junior 2023-08-08 Annually 5 0.59%
HATSUN.NS Dividend Junior 2023-07-27 Annually 10 0.45%
BECTORFOOD.NS Dividend Junior 2023-09-22 Semi-Annually 4 0.39%
PSPPROJECT.NS Dividend Junior 2023-09-01 Annually 8 0.49%
KEC.NS Dividend Junior 2023-07-25 Annually 19 0.55%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06801.5008.6410.00[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM0.2011.5008.8810.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM8.411.0008.008.00[3 - 30]
operatingCashFlowPerShareTTM10.962.006.3510.00[0 - 30]
freeCashFlowPerShareTTM10.962.004.529.04[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.3221.0007.967.96[0.2 - 0.8]
operatingProfitMarginTTM0.1051.0009.919.91[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score4.77

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM25.911.0007.480[1 - 100]
returnOnEquityTTM0.2012.509.2810.00[0.1 - 1.5]
freeCashFlowPerShareTTM10.962.006.359.04[0 - 30]
dividendYielPercentageTTM0.1971.5005.080[0 - 0.4]
operatingCashFlowPerShareTTM10.962.006.3510.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.3731.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.03801.000-1.5500[0.1 - 0.5]
Total Score3.36

Aarti Drugs Limited

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators